Measles Vaccine in HCW

Study Overview
=================
Brief Summary
-----------------
Till now, mortality reports among children below 9 years remains extremely low despite that the incidence of death toll is high and exceeding 50,000 patients among older population, One speculation for lower SARS infectivity is that cross-protective antibodies against measles vaccine ( MV). In mice susceptible to measles virus, recombinant MV induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV, The primary objective of the present study is to determine the benefit of measles vaccine in health care professional to decrease the incidence of COVID-19. We Hypothesized that, measles vaccine may lower the incidence of serologically proven SARS-CoV-2 infection and reported respiratory illness

Official Title
-----------------
Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Drug: Measles-Mumps-Rubella Vaccine
* Drug: Placebos


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-50 years old Subjects who are willing to comply with the requirements of the study protocol and scheduled visits (for example, completion of the subject diary, return for follow-up visits) and who are willing to make themselves available for the duration of the study with access to a consistent means of telephone contact Exclusion Criteria: acute severe illness recent receipt of a blood product history of thrombocytopenia Pregnant females any chronic medical condition Any participant receiving any immune suppressive medication Immunocompromised staff Participants who have egg allergy Participants who care for immune compromised hosts Participants who test positive for COVID-19 serology prior to randomization

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MMR vaccine<br>0.5 ml subcutaneous of MMR vaccine will be injected in posterior triceps aspect of upper arm | Drug: Measles-Mumps-Rubella Vaccine<br>* Measles mumps Rubella vaccine is a weak attenuated life vaccine<br>|
| Placebo Comparator: Control<br>0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm | Drug: Placebos<br>* 0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| COVID-19 disease incidence | Number of participants with asymptomatic or mild COVID-19 disease defined as fever (using self-reported questionnaire), plus at least one sign or symptom of respiratory disease including cough, runny/blocked nose (using self-reported questionnaire), plus positive SARS-Cov-2 test (PCR or serology) | Time Frame: Measured over the 6 months following randomization | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SARS-CoV-2 pneumonia | Number of pneumonia cases (abnormal chest X-ray) (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test | Time Frame: Measured over the 6 months following randomization | 
| Critical care admission duration with SARS-CoV-2 | Number of days admitted to critical care (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test | Time Frame: Measured over the 6 months following randomization | 
| Oxygen therapy with SARS-CoV-2 | Need for oxygen therapy (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test | Time Frame: Measured over the 6 months following randomization | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MMR vaccine, Respiratory failure,